Medical Equipment Financing Market by Equipment Type (Cardiovascular Equipment, Dental Equipment, Imaging Equipment), Financing Model (Equipment As Service, Lease, Loan), Equipment Age, End User - Global Forecast 2025-2032
Description
The Medical Equipment Financing Market was valued at USD 159.70 billion in 2024 and is projected to grow to USD 172.24 billion in 2025, with a CAGR of 8.69%, reaching USD 311.09 billion by 2032.
An authoritative introduction to medical equipment financing that frames strategic priorities, risk vectors, stakeholder incentives and operational enablers for decision makers
This executive summary establishes a strategic framing of medical equipment financing that foregrounds capital allocation, procurement behavior, and the interplay between clinical innovation and funding mechanisms. The objective is to present a concise but comprehensive orientation that equips senior executives, finance leaders, and procurement specialists with the context necessary to evaluate options, assess risk, and prioritize near-term actions.
Healthcare providers and equipment vendors operate in an environment where technology cycles accelerate, regulatory regimes evolve, and payment models shift. Consequently, financing decisions are no longer solely transactional; they are integral to how organizations deliver care, manage obsolescence, and align with value-based objectives. This introduction clarifies the principal drivers of financing activity, identifies the key stakeholder incentives that shape deal structures, and highlights operational enablers required to translate financing into measurable outcomes.
Mapping transformative shifts reshaping medical equipment financing: technology adoption, regulatory evolution, procurement models, and capital structures driving new value pathways
The financing landscape for medical equipment is undergoing a series of transformative shifts that are changing how capital is sourced, allocated, and serviced. Technological advances such as the maturation of advanced imaging modalities, robotics in surgery, and integrated diagnostic platforms increase the clinical value of equipment while simultaneously raising acquisition and lifecycle costs. As a result, providers and financiers are exploring alternative procurement mechanisms and contract structures to align asset performance with payment obligations.
Equally important, regulatory and compliance pressures are prompting greater transparency in procurement and operating contracts. Licensing, cybersecurity, and interoperability requirements are now core considerations in financing diligence, and they influence risk assessment and collateral valuation. Moreover, the increasing commercialization of services attached to equipment-ranging from remote monitoring to AI-driven diagnostics-reshapes the revenue profile of devices and encourages finance models that incorporate service-level components. Collectively, these dynamics create new opportunities for structured financing, vendor-backed solutions, and subscription arrangements that reconcile technological ambition with fiscal discipline.
Assessing cumulative impacts of United States tariffs in 2025 on medical equipment financing, procurement complexity, supply chain resilience, and cross-border capital flows
The introduction of tariffs in 2025 has introduced a material layer of complexity to cross-border procurement, supply chain planning, and capital allocation for medical equipment. Tariff-related cost pressures increase the effective purchase price for equipment components or finished systems sourced from affected jurisdictions, prompting procurement offices to reassess incumbent supplier relationships and total cost of ownership calculations. In response, organizations are recalibrating financing structures to preserve cash flow and to mitigate the short-term impact on operating budgets.
Beyond direct price effects, tariffs influence supply chain resilience and inventory strategies. Providers and vendors are more frequently incorporating contingency planning into financing covenants, with an emphasis on flexible terms that accommodate lead-time variability and potential component substitution. Meanwhile, financiers and lessors are revising credit assessment frameworks to account for geopolitical risk layers that can affect equipment availability and residual value. In sum, the tariff environment has amplified the need for adaptive financing solutions and underscores the importance of contractual agility when managing imported medical technologies.
Segment-driven insights revealing nuanced financing dynamics across equipment types, end users, financing models, equipment age, and contract term structures
A segmentation-led perspective reveals distinct financing dynamics across equipment types, end users, financing models, equipment age, and contract terms, each exhibiting divergent risk and value characteristics. Based on equipment type, the landscape spans Cardiovascular Equipment, Dental Equipment, Imaging Equipment, Life Sciences Equipment, and Surgical Equipment; within Imaging Equipment, there are specific considerations for CT Scanners, MRI Systems, Ultrasound Systems, and X-Ray Systems, while the Surgical Equipment category further differentiates Electrosurgical Units, Endoscopy Systems, and Robotic Surgery Systems. These distinctions matter because modality-specific maintenance burdens, service dependencies, and upgrade cycles materially influence the attractiveness of leasing, subscription, or loan structures.
Based on end user, financing preferences and underwriting criteria vary across Ambulatory Surgical Centers, Clinics, Diagnostic Centers, Hospitals, and Research Institutes; Ambulatory Surgical Centers further split into Ophthalmic Centers and Orthopedic Centers, Clinics into Multi-Specialty Clinics and Specialty Clinics, Diagnostic Centers into Pathology Labs and Radiology Centers, Hospitals into Private Hospitals and Public Hospitals, and Research Institutes into Academic Institutes and Government Research Centers. The differing cash flow profiles, procurement authorities, and reimbursement models across these end-user types affect tenor, collateral requirements, and the appetite for equipment-as-a-service arrangements.
Based on financing model, the market is characterized by Equipment As Service, Lease, Loan, and Vendor Financing options; the Equipment As Service pathway often manifests as a subscription model, Lease can be structured as a finance lease or operating lease, Loan products appear as secured or unsecured instruments, and Vendor Financing typically emerges through distributor financing or manufacturer financing. These choices reflect trade-offs between balance-sheet treatment, operational flexibility, and maintenance obligations, so providers and vendors must align financing with clinical deployment plans and total lifecycle economics.
Based on equipment age, distinctions between New Equipment and Refurbished Equipment drive different underwriting approaches; New Equipment is often procured as custom builds or off-the-shelf units, while Refurbished Equipment is graded into Grade A and Grade B categories that carry differential residual value expectations and servicing commitments. Finally, based on term, contracts break down into Long Term and Short Term tenors; Long Term arrangements commonly extend from 12 to 36 months or beyond 36 months, while Short Term contracts span up to 6 months or 6 to 12 months. Term selection has direct implications for depreciation schedules, upgrade pathways, and the alignment of payments with expected clinical utility.
Regional intelligence dissecting demand drivers, reimbursement ecosystems, supply chain footprints, and financing preferences across major geographic blocs
Regional variation shapes procurement behavior, financing options, and operational priorities, and these differences have material implications for market players and financiers. In the Americas, financing strategies are frequently influenced by a concentrated private provider base, diverse payer arrangements, and an appetite for bundled service contracts that tie asset performance to payment. Consequently, vendors and lessors emphasize flexible commercial models, strong after-sales support, and compliance with regional regulatory expectations.
In Europe, Middle East & Africa, reimbursement structures and public procurement rules create heterogeneity that favors tailored financing solutions; public hospitals and government research centers often pursue long-term leases or vendor-supported programs that reduce immediate capital outlays, while private institutions may prioritize market differentiation through advanced imaging and robotic systems. Across Asia-Pacific, rapid adoption of cutting-edge modalities coexists with varying degrees of local manufacturing and refurbishing activity, which influences financing pathways such as vendor financing or structured operating leases. Recognizing these regional distinctions enables stakeholders to craft geographically appropriate pricing, service-level agreements, and risk-sharing mechanisms.
Competitive and corporate insights highlighting strategic positioning, partnership archetypes, product-service convergence, and financing innovation among key players
Leading companies and institutional players are evolving their value propositions by integrating financing with product and service portfolios to reduce barriers to adoption and to capture recurring revenue streams. Strategic partnerships between manufacturers, distributors, and financial institutions are enabling bundled offers that combine equipment, installation, training, and performance guarantees under unified contract terms. These collaborations improve predictability for buyers while creating differentiated revenue models for vendors.
At the same time, some corporate actors are investing in capabilities that support lifecycle services, remote diagnostics, and data analytics, which enhance asset uptime and inform residual value assessments. These investments have become central to competitive positioning because they allow firms to underwrite more innovative financing structures and to extend the useful economic life of assets. For procurement and finance teams evaluating vendor selection, the presence of integrated financing, demonstrated service networks, and clear performance metrics are increasingly decisive criteria.
Actionable strategic recommendations for industry leaders to optimize financing models, mitigate regulatory and tariff risks, and accelerate adoption through partnerships
Industry leaders should pursue several actionable steps to strengthen resilience, optimize capital efficiency, and accelerate clinically meaningful technology adoption. First, align financing design with clinical and operational objectives by incorporating performance-based terms, flexible upgrade clauses, and service level commitments that protect operating budgets and clinical continuity. This approach fosters shared incentives between providers and suppliers and reduces friction at the point of deployment.
Second, diversify financing channels to balance liquidity and risk exposure, combining vendor financing, subscription arrangements, and traditional lease or loan instruments as appropriate to modality and end-user profiles. Third, invest in governance and diligence capabilities that explicitly account for geopolitical risk, tariff exposure, and supply chain concentration so that covenants and contingency plans can be enacted without disrupting care delivery. Finally, prioritize partnerships that integrate lifecycle services, remote monitoring, and analytics to improve uptime and residual value visibility; these capabilities enable more competitive financing terms and support long-term strategic alignment between capital providers and clinical operators.
Transparent research methodology detailing data sources, qualitative and quantitative approaches, validation protocols, and triangulation techniques used in this analysis
The analysis underpinning this summary integrates primary qualitative interviews with finance executives, procurement leads, and clinical technology managers, together with secondary research into regulatory frameworks, device classifications, and procurement practices. Data validation relied on cross-checking vendor program descriptions, published guidance from regulatory agencies, and anonymized operational case studies that illustrate contract performance and lifecycle outcomes.
To ensure rigor, thematic findings were triangulated across multiple sources and iterated with subject-matter experts representing equipment vendors, independent lessors, and health system finance teams. The methodology emphasized reproducibility by documenting assumptions used in financing comparisons, standardizing metrics for contract evaluation, and applying consistent criteria for equipment age and condition gradations. This structured approach delivers a robust foundation for the insights and recommendations presented herein.
Concise conclusion synthesizing implications for stakeholders, priority areas for investment, and the near-term operational focus needed to navigate disruption
In conclusion, the intersection of advancing clinical technology, evolving procurement preferences, and new regulatory dynamics is reshaping how medical equipment is financed and deployed. Stakeholders who adopt flexible contract designs, integrate lifecycle services, and proactively manage geopolitical and tariff-related risk will be better positioned to preserve capital, enhance operational continuity, and sustain clinical innovation.
Moving forward, the emphasis for leaders should be on aligning financing with measurable performance outcomes, diversifying funding channels to reflect modality- and region-specific realities, and reinforcing partnerships that deliver predictable service and upgrade paths. These priorities will determine which organizations can translate capital investments into improved patient care and long-term financial stability.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction to medical equipment financing that frames strategic priorities, risk vectors, stakeholder incentives and operational enablers for decision makers
This executive summary establishes a strategic framing of medical equipment financing that foregrounds capital allocation, procurement behavior, and the interplay between clinical innovation and funding mechanisms. The objective is to present a concise but comprehensive orientation that equips senior executives, finance leaders, and procurement specialists with the context necessary to evaluate options, assess risk, and prioritize near-term actions.
Healthcare providers and equipment vendors operate in an environment where technology cycles accelerate, regulatory regimes evolve, and payment models shift. Consequently, financing decisions are no longer solely transactional; they are integral to how organizations deliver care, manage obsolescence, and align with value-based objectives. This introduction clarifies the principal drivers of financing activity, identifies the key stakeholder incentives that shape deal structures, and highlights operational enablers required to translate financing into measurable outcomes.
Mapping transformative shifts reshaping medical equipment financing: technology adoption, regulatory evolution, procurement models, and capital structures driving new value pathways
The financing landscape for medical equipment is undergoing a series of transformative shifts that are changing how capital is sourced, allocated, and serviced. Technological advances such as the maturation of advanced imaging modalities, robotics in surgery, and integrated diagnostic platforms increase the clinical value of equipment while simultaneously raising acquisition and lifecycle costs. As a result, providers and financiers are exploring alternative procurement mechanisms and contract structures to align asset performance with payment obligations.
Equally important, regulatory and compliance pressures are prompting greater transparency in procurement and operating contracts. Licensing, cybersecurity, and interoperability requirements are now core considerations in financing diligence, and they influence risk assessment and collateral valuation. Moreover, the increasing commercialization of services attached to equipment-ranging from remote monitoring to AI-driven diagnostics-reshapes the revenue profile of devices and encourages finance models that incorporate service-level components. Collectively, these dynamics create new opportunities for structured financing, vendor-backed solutions, and subscription arrangements that reconcile technological ambition with fiscal discipline.
Assessing cumulative impacts of United States tariffs in 2025 on medical equipment financing, procurement complexity, supply chain resilience, and cross-border capital flows
The introduction of tariffs in 2025 has introduced a material layer of complexity to cross-border procurement, supply chain planning, and capital allocation for medical equipment. Tariff-related cost pressures increase the effective purchase price for equipment components or finished systems sourced from affected jurisdictions, prompting procurement offices to reassess incumbent supplier relationships and total cost of ownership calculations. In response, organizations are recalibrating financing structures to preserve cash flow and to mitigate the short-term impact on operating budgets.
Beyond direct price effects, tariffs influence supply chain resilience and inventory strategies. Providers and vendors are more frequently incorporating contingency planning into financing covenants, with an emphasis on flexible terms that accommodate lead-time variability and potential component substitution. Meanwhile, financiers and lessors are revising credit assessment frameworks to account for geopolitical risk layers that can affect equipment availability and residual value. In sum, the tariff environment has amplified the need for adaptive financing solutions and underscores the importance of contractual agility when managing imported medical technologies.
Segment-driven insights revealing nuanced financing dynamics across equipment types, end users, financing models, equipment age, and contract term structures
A segmentation-led perspective reveals distinct financing dynamics across equipment types, end users, financing models, equipment age, and contract terms, each exhibiting divergent risk and value characteristics. Based on equipment type, the landscape spans Cardiovascular Equipment, Dental Equipment, Imaging Equipment, Life Sciences Equipment, and Surgical Equipment; within Imaging Equipment, there are specific considerations for CT Scanners, MRI Systems, Ultrasound Systems, and X-Ray Systems, while the Surgical Equipment category further differentiates Electrosurgical Units, Endoscopy Systems, and Robotic Surgery Systems. These distinctions matter because modality-specific maintenance burdens, service dependencies, and upgrade cycles materially influence the attractiveness of leasing, subscription, or loan structures.
Based on end user, financing preferences and underwriting criteria vary across Ambulatory Surgical Centers, Clinics, Diagnostic Centers, Hospitals, and Research Institutes; Ambulatory Surgical Centers further split into Ophthalmic Centers and Orthopedic Centers, Clinics into Multi-Specialty Clinics and Specialty Clinics, Diagnostic Centers into Pathology Labs and Radiology Centers, Hospitals into Private Hospitals and Public Hospitals, and Research Institutes into Academic Institutes and Government Research Centers. The differing cash flow profiles, procurement authorities, and reimbursement models across these end-user types affect tenor, collateral requirements, and the appetite for equipment-as-a-service arrangements.
Based on financing model, the market is characterized by Equipment As Service, Lease, Loan, and Vendor Financing options; the Equipment As Service pathway often manifests as a subscription model, Lease can be structured as a finance lease or operating lease, Loan products appear as secured or unsecured instruments, and Vendor Financing typically emerges through distributor financing or manufacturer financing. These choices reflect trade-offs between balance-sheet treatment, operational flexibility, and maintenance obligations, so providers and vendors must align financing with clinical deployment plans and total lifecycle economics.
Based on equipment age, distinctions between New Equipment and Refurbished Equipment drive different underwriting approaches; New Equipment is often procured as custom builds or off-the-shelf units, while Refurbished Equipment is graded into Grade A and Grade B categories that carry differential residual value expectations and servicing commitments. Finally, based on term, contracts break down into Long Term and Short Term tenors; Long Term arrangements commonly extend from 12 to 36 months or beyond 36 months, while Short Term contracts span up to 6 months or 6 to 12 months. Term selection has direct implications for depreciation schedules, upgrade pathways, and the alignment of payments with expected clinical utility.
Regional intelligence dissecting demand drivers, reimbursement ecosystems, supply chain footprints, and financing preferences across major geographic blocs
Regional variation shapes procurement behavior, financing options, and operational priorities, and these differences have material implications for market players and financiers. In the Americas, financing strategies are frequently influenced by a concentrated private provider base, diverse payer arrangements, and an appetite for bundled service contracts that tie asset performance to payment. Consequently, vendors and lessors emphasize flexible commercial models, strong after-sales support, and compliance with regional regulatory expectations.
In Europe, Middle East & Africa, reimbursement structures and public procurement rules create heterogeneity that favors tailored financing solutions; public hospitals and government research centers often pursue long-term leases or vendor-supported programs that reduce immediate capital outlays, while private institutions may prioritize market differentiation through advanced imaging and robotic systems. Across Asia-Pacific, rapid adoption of cutting-edge modalities coexists with varying degrees of local manufacturing and refurbishing activity, which influences financing pathways such as vendor financing or structured operating leases. Recognizing these regional distinctions enables stakeholders to craft geographically appropriate pricing, service-level agreements, and risk-sharing mechanisms.
Competitive and corporate insights highlighting strategic positioning, partnership archetypes, product-service convergence, and financing innovation among key players
Leading companies and institutional players are evolving their value propositions by integrating financing with product and service portfolios to reduce barriers to adoption and to capture recurring revenue streams. Strategic partnerships between manufacturers, distributors, and financial institutions are enabling bundled offers that combine equipment, installation, training, and performance guarantees under unified contract terms. These collaborations improve predictability for buyers while creating differentiated revenue models for vendors.
At the same time, some corporate actors are investing in capabilities that support lifecycle services, remote diagnostics, and data analytics, which enhance asset uptime and inform residual value assessments. These investments have become central to competitive positioning because they allow firms to underwrite more innovative financing structures and to extend the useful economic life of assets. For procurement and finance teams evaluating vendor selection, the presence of integrated financing, demonstrated service networks, and clear performance metrics are increasingly decisive criteria.
Actionable strategic recommendations for industry leaders to optimize financing models, mitigate regulatory and tariff risks, and accelerate adoption through partnerships
Industry leaders should pursue several actionable steps to strengthen resilience, optimize capital efficiency, and accelerate clinically meaningful technology adoption. First, align financing design with clinical and operational objectives by incorporating performance-based terms, flexible upgrade clauses, and service level commitments that protect operating budgets and clinical continuity. This approach fosters shared incentives between providers and suppliers and reduces friction at the point of deployment.
Second, diversify financing channels to balance liquidity and risk exposure, combining vendor financing, subscription arrangements, and traditional lease or loan instruments as appropriate to modality and end-user profiles. Third, invest in governance and diligence capabilities that explicitly account for geopolitical risk, tariff exposure, and supply chain concentration so that covenants and contingency plans can be enacted without disrupting care delivery. Finally, prioritize partnerships that integrate lifecycle services, remote monitoring, and analytics to improve uptime and residual value visibility; these capabilities enable more competitive financing terms and support long-term strategic alignment between capital providers and clinical operators.
Transparent research methodology detailing data sources, qualitative and quantitative approaches, validation protocols, and triangulation techniques used in this analysis
The analysis underpinning this summary integrates primary qualitative interviews with finance executives, procurement leads, and clinical technology managers, together with secondary research into regulatory frameworks, device classifications, and procurement practices. Data validation relied on cross-checking vendor program descriptions, published guidance from regulatory agencies, and anonymized operational case studies that illustrate contract performance and lifecycle outcomes.
To ensure rigor, thematic findings were triangulated across multiple sources and iterated with subject-matter experts representing equipment vendors, independent lessors, and health system finance teams. The methodology emphasized reproducibility by documenting assumptions used in financing comparisons, standardizing metrics for contract evaluation, and applying consistent criteria for equipment age and condition gradations. This structured approach delivers a robust foundation for the insights and recommendations presented herein.
Concise conclusion synthesizing implications for stakeholders, priority areas for investment, and the near-term operational focus needed to navigate disruption
In conclusion, the intersection of advancing clinical technology, evolving procurement preferences, and new regulatory dynamics is reshaping how medical equipment is financed and deployed. Stakeholders who adopt flexible contract designs, integrate lifecycle services, and proactively manage geopolitical and tariff-related risk will be better positioned to preserve capital, enhance operational continuity, and sustain clinical innovation.
Moving forward, the emphasis for leaders should be on aligning financing with measurable performance outcomes, diversifying funding channels to reflect modality- and region-specific realities, and reinforcing partnerships that deliver predictable service and upgrade paths. These priorities will determine which organizations can translate capital investments into improved patient care and long-term financial stability.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of digital credit scoring and AI-driven underwriting for faster equipment financing approvals
- 5.2. Integration of pay-per-use and outcome-based reimbursement models in medical device financing arrangements
- 5.3. Emergence of green and sustainable financing products for energy efficient hospital equipment acquisitions
- 5.4. Implementation of cloud-based financing platforms for seamless equipment procurement and loan management
- 5.5. Expansion of public-private partnership driven funding solutions to support rural healthcare equipment upgrades
- 5.6. Rise of cross-border and export credit financing to facilitate global distribution of diagnostic imaging systems
- 5.7. Growing influence of regulatory incentives and tax credit programs on leasing of advanced medical technology
- 5.8. Increased demand for short term bridge loans to address pandemic-induced equipment funding gaps in hospitals
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Medical Equipment Financing Market, by Equipment Type
- 8.1. Cardiovascular Equipment
- 8.2. Dental Equipment
- 8.3. Imaging Equipment
- 8.3.1. CT Scanners
- 8.3.2. MRI Systems
- 8.3.3. Ultrasound Systems
- 8.3.4. X-Ray Systems
- 8.4. Life Sciences Equipment
- 8.5. Surgical Equipment
- 8.5.1. Electrosurgical Units
- 8.5.2. Endoscopy Systems
- 8.5.3. Robotic Surgery Systems
- 9. Medical Equipment Financing Market, by Financing Model
- 9.1. Equipment As Service
- 9.2. Lease
- 9.2.1. Finance Lease
- 9.2.2. Operating Lease
- 9.3. Loan
- 9.3.1. Secured Loan
- 9.3.2. Unsecured Loan
- 9.4. Vendor Financing
- 9.4.1. Distributor Financing
- 9.4.2. Manufacturer Financing
- 10. Medical Equipment Financing Market, by Equipment Age
- 10.1. New Equipment
- 10.1.1. Custom Equipment
- 10.1.2. Off The Shelf
- 10.2. Refurbished Equipment
- 10.2.1. Grade A
- 10.2.2. Grade B
- 11. Medical Equipment Financing Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.1.1. Ophthalmic Centers
- 11.1.2. Orthopedic Centers
- 11.2. Clinics
- 11.2.1. Multi-Specialty Clinics
- 11.2.2. Specialty Clinics
- 11.3. Diagnostic Centers
- 11.3.1. Pathology Labs
- 11.3.2. Radiology Centers
- 11.4. Hospitals
- 11.4.1. Private Hospitals
- 11.4.2. Public Hospitals
- 11.5. Research Institutes
- 11.5.1. Academic Institutes
- 11.5.2. Government Research Centers
- 12. Medical Equipment Financing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Medical Equipment Financing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Medical Equipment Financing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. American Express Company
- 15.3.2. Amur equipment Finance
- 15.3.3. Axis Bank Limited
- 15.3.4. Bajaj Finserv Limited
- 15.3.5. Blue Bridge Financial, Inc.
- 15.3.6. Clix Capital Services Private Limited
- 15.3.7. CMS Funding
- 15.3.8. EverBank, N.A.
- 15.3.9. First American Equipment Finance by City National Bank company
- 15.3.10. HDFC Bank Limited
- 15.3.11. Hero FinCorp
- 15.3.12. ICICI Bank Limited
- 15.3.13. IndusInd Bank Limited
- 15.3.14. JPMorgan Chase & Co.
- 15.3.15. Macquarie Group Limited
- 15.3.16. Moneywise Financial Services Private Limited
- 15.3.17. National Funding
- 15.3.18. Poonawalla Fincorp Limited
- 15.3.19. Siemens AG
- 15.3.20. SLR Healthcare ABL
- 15.3.21. Societe Generale
- 15.3.22. State Bank of India
- 15.3.23. Tata Capital Limited
- 15.3.24. TD Bank, N.A.
- 15.3.25. Truist Bank
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
